Islet Amyloid Polypeptide

Protein Misfolding Diseases: Current and Emerging Principles and Therapies

Volumn , Issue , 2010, Pages 517-541

  Abedini, Andisheh ^a   Raleigh, Daniel P ^b  

^a Columbia University ^*  (United States)

^b STONY BROOK UNIVERSITY   (United States)

Author keywords

Double nucleation model to rationalize IAPP fibrillization kinetics; IAPP, role in maintaining glucose homeostasis by suppression of insulin mediated glucose uptake; islet amyloid polypeptide (IAPP) in pancreases of patients with type 2 diabetes

Indexed keywords

EID: 84886112034     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470572702.ch23     Document Type: Chapter

References (147)

1. Opie, E.L. (1901). The relation of diabetes mellitus to lesions of the pancreas: hyaline degeneration of the islets of Langerhans. J Exp Med, 5, 527-540.
2. Weichselbaum, A., Stangl, E. (1901). Zur Kenntis der feineren Veränderungen des Pankreas bei Diabetes mellitus. Wien Klin Wochenschr, 14, 968-972.
3. Westermark, P., Wernstedt, C., Wilander, E., Hayden, D.W., O'Brien, T.D., Johnson, K.H. (1987). Amyloid fibrils in human insulinoma and islets of Langerhans of the diabetic cat are derived from a neuropeptide-like protein also present in normal islet cells. Proc Natl Acad Sci U S A, 84, 3881-3885.
4. Cooper, G.J.S., Willis, A.C., Clark, A., Turner, R.C., Sim, R.B., Reid, K.B.M. (1987). Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proc Natl Acad Sci U S A, 84, 8628-8632.
5. Cooper, G.J.S. (1994). IAPP compared with calcitonin gene-related peptide: structure, biology, and relevance to metabolic disease. Endocrine Rev, 15, 163-201.
6. Hay, D.L., Christopoulos, G., Christopoulos, A., Sexton, P.M. (2004). Amylin receptors: molecular composition and pharmacology. Biochem Soc Trans, 32, 865-867.
7. McLatchie, L.M., Fraser, N.J., Main, M.J., Wise, A., Brown, J., Thompson, N., Solari, R., Lee, M.G., Foord, S.M. (1998). RAMPS regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature, 393, 333-339.
8. Sanke, T., Bell, G.I., Sample, C., Rubenstein, A.H., Steiner, D.F. (1988). Islet amyloid peptide is derived from an 89-amino acid precursor by proteolytic processing. J Biol Chem, 263, 17243-17246.
9. Marzban, T., Trigo-Gonzalez, G., Verchere, C.B. (2005). Processing of pro-islet amyloid polypeptide in the constitutive and regulated secretory pathways of beta cells. Mol Endocrinol, 19, 2154-2163.
10. Lukinius, A., Wilander, E., Westermark, G.T., Engström, U., Westermark, P. (1989). Co-localization of islet amyloid polypeptide and insulin in the beta-cell secretory granules of the human pancreatic islets. Diabetologia, 32, 240-244.
11. Kahn, S.E., D'Alessio, D.A., Schwartz, M.W., Fujimoto, W.Y., Ensinck, J.W., Taborsky, G.J., Porte, D. (1990). Evidence of cosecretion of islet amyloid polypeptide and insulin by beta-cells. Diabetes, 39, 634-638.
12. Hanabusa, T., Kuba, K., Oki, C., Nakano, Y., Okai, K., Sanke, T., Nanjo, K. (1992). Islet amyloid polypeptide (IAPP) secretion from islet cells and its plasma concentration in patients with non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract, 15, 89-96.
13. Stridsberg, M., Sandler, S., Wilander, E. (1993). Cosecretion of islet amyloid polypeptide (IAPP) and insulin from isolated rat pancreatic islets following stimulation or inhibition of beta-cell function. Regul Pept, 45, 363-370.
14. Kahn, S.E., Andrikopoulos, S., Verchere, C.B. (1999). Islet amyloid: a long recognized but underappreciated pathological feature of type II diabetes. Diabetes, 48, 241-246.
15. Hull, R.L., Westermark, G.T., Westermark, P., Kahn, S.E. (2004). Islet amyloid: a critical entity in the pathogenesis of type 2 diabetes. J Clin Endocrinol Metab, 89, 3629-3643.
16. Jaikaran, E., Clark, A. (2001). Islet amyloid and type 2 diabetes: from molecular misfolding to islet pathophysiology. Biochim Biophys Acta, 1537, 179-203.
17. Phillips, L.K., Horowitz, M. (2006). Amylin. Curr Opin Endocrinol Diabetes, 13, 191-198.
18. Hoppener, J.W.H., Lips, C.J.M. (2006). Role of islet amyloid in type 2 diabetes mellitus. Int J Biochem Cell Biol, 38, 726-736.
19. Johnson, K.H., O'Brien, T.D., Betsholtz, C., Westermark, P. (1989). Islet amyloid, islet-amyloid polypeptide, and diabetes mellitus. N Engl J Med, 321, 513-518.
20. Clark, A., Nilsson, M.R. (2004). Islet amyloid: a complication of islet cell dysfunction or an aetiological factor in type 2 diabetes? Diabetologia, 47, 157-169.
21. Konarkowska, B., Aiteken, J.F., Kistler, J., Zhang, S. P., Cooper, G.J.S. (2006). The aggregation potential of human amylin determines its cytotoxicity towards islet beta-cells. FEBS J, 273, 3614-3624.
22. Clark, A., Wells, C.A., Buley, I.D., Cruickshank, J.K., Vanhegan, R.I., Matthews, D.R., Cooper, G.J.S., Holman, R.R., Turner, R.C. (1988). Islet amyloid, increased a-cells, reduced b-cells and exocrine fibrosis: quantitative changes in the pancreas in type 2 diabetes. Diabetes Res Clin Pract, 9, 151-159.
23. Lorenzo, A., Razzaboni, B., Weir, G.C., Yankner, B.A. (1994). Pancreatic islet cell toxicity of amylin associated with type 2 diabetes mellitus. Nature, 368, 756-760.
24. Rocken, C., Linke, R.P., Saeger, W. (1992). Immunohistology of islet amyloid polypeptide in diabetes mellitus: semiquantitative studies in a post-mortem series. Virchows Arch A, 421, 339-344.
25. Hayden, M.R., Karuparthi, R. R., Manrique, C.M., Lastra, G. Habibi, J., Sowers, J.R. (2007). Longitudinal ultrastructure study of islet amyloid in the HIP rat model of type 2 diabetes mellitus. Exp Biol Med, 232, 772-779.
26. Koning, E.J., Bodkin, N.L., Hansen, B.C., Clark, A. (1993). Diabetes mellitus in macaca mulatta monkeys is characterized by islet amyloidosis and reduction in b-cell population. Diabetologica, 36, 378-384.
27. Wang, F., Hull, R.L., Vidal, J., Cnop, M., Kahn, S.E. (2001). Islet amyloid develops diffusely throughout the pancreas before becoming severe and replacing endocrine cells. Diabetes, 50, 2514-2520.
28. Kayed, R., Head, E., Thompson, J.L., McIntire, T.M., Milton, S.C., Cotman, C.W, Glabe, C.G. (2003). Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science, 300, 486-489.
29. Janson, J., Ashley, R.H., Harrison, D., McIntyre, S., Butler, P.C. (1999). The mechanism of islet amyloid polypeptide toxicity is membrane disruption by intermediate-sized toxic amyloid particles. Diabetes, 48, 491-498.
30. Ritzel, R.A., Meier, J.J., Lin, C.-Y., Veldhuis, J.D., Butler, P.C. (2007). Human islet amyloid polypeptide oligomers disrupt cell coupling, induce apoptosis, and impair insulin secretion in isolated human islets. Diabetes, 56, 65-71.
31. Butler, P.C., Chou, J., Carter, W.B., Wang, Y.N., Bu, B.H., Chang, D., Chang, J.K., Rizza, R.A. (1990). Effects of meal ingestion on plasma amylin concentration in NIDDM and nondiabetic humans. Diabetes, 39, 752-756.
32. Leighton, B., Cooper, G.J.S. (1988). Pancreatic amylin and calcitonin gene-related peptide cause resistance to insulin in skeletal-muscle in vitro. Nature, 335, 632-635.
33. Ohsawa, H., Kanatsuka, A., Yamaguchi, T., Makino, H., Yoshida, S. (1989). Islet amyloid polypeptide inhibits glucose-stimulated insulin secretion from isolated rat pancreatic islets. Biochem Biophys Res Commun, 160, 961-967.
34. Akesson, B., Panagiotidis, G., Westermark, P., Lundquist, I. (2003). Islet amyloid polypeptide inhibits glucagon release and exerts a dual action on insulin release from isolated islets. Regul Pept, 111, 55-60.
35. Wookey, P.J., Tikellis, C., Du, H.C., Qin, H.F., Sexton, P.M., Cooper, M.E. (1996). Amylin binding in rat renal-cortex, stimulation of adenylyl-cyclase, and activation of plasma-renin. Am J Phys, 39, F289-F294.
36. Clementi, G., Caruso, A., Cutuli, V.M.C., de Bernardis, E., Prato, A., Amico-Roxas, M. (1996). Amylin given by central or peripheral routes decreases gastric emptying and intestinal transit in the rat. Experientia, 52, 677-679.
37. Rushing, P.A., Hagan, M.M., Seeley, R.J., Lutz, T.A., D'Alessio, D.A., Air, E.L., Woods, S.C. (2001). Inhibition of central amylin signaling increases food intake and body adiposity in rats. Endocrinology, 142, 5035-5038.
38. Wookey, P.J., Xuerebi, L., Tikellis, C., Cooper, G.J.S. (2003). Amylin in the periphery. Sci World, 3, 163-175.
39. Riediger, T., Rauch, M., Schmid, H.A. (1999). Actions of amylin on subfornical organ neurons and on drinking behaviour in rats. Am J Physiol, 276, R514-R521.
40. Chin, S.Y., Hall, J.M., Brain, S.D., Morton, I.K.M. (1994). Vasodilator responses to calcitonin gene-related peptide and IAPP in the rat isolated-perfused kidney are mediated via CGRP1 receptors. J Pharm Exp Ther, 269, 989-992.
41. Reidelberger, R.D., Haver, A.C., Arnelo, U., Smith, D.D., Schaffert, C.S., Permert, J. (2004). Amylin receptor blockade stimulates food intake in rats. Am J Physiol Regul Integr Comp Physiol, 287, R568-R574.
42. Wang, J., Xu, J., Finnerty, J., Furuta, M., Steiner, D.F., Verchere, C.B. (2001). The prohormone convertase enzyme 2 (PC2) is essential for processing proislet amyloid polypeptide at the NH2-terminal cleavage site. Diabetes, 50, 534-539.
43. Marzban, L., Trigo-Gonzalez, G., Zhu, X., Rhodes, C.J., Halban, P.A., Steiner, D.F., Verchere, C.B. (2004). Role of b-cell prohormone convertase PC (1/3) in processing of pro-islet amyloid polypeptide. Diabetes, 53, 141-148.
44. Roberts, A.N., Leighton, B., Todd, J.A., Cockburn, D., Schofield, P.N., Sutton, R., Holt, S., Boyd, Y., Day, A.J., Foot, E.A., et al. (1998). Molecular and functional characterization of amylin, a peptide associated with type 2 diabetes mellitus. Proc Natl Acad Sci U S A, 86, 9662-9666.
45. Hutton, J.C. (1989). The insulin secretory granule. Diabetologia, 32, 271-281.
46. Hutton, J.C. (1982). The internal pH and membrane potential of the insulinsecretory granule. Biochem J, 204, 171-178.
47. Chargé , S.B.P., de Koning, E.J.P., Clark, A. (1995). Effect of pH and insulin on fibrillogenesis of islet amyloid polypeptide in vitro. Biochemistry, 34, 14588-14593.
48. Abedini, A., Raleigh, D.P. (2005). The role of His-18 in amyloid formation by human islet amyloid polypeptide. Biochemistry, 44, 16284-16291.
49. Westermark, P., Li, Z.C., Westermark, G.T., Leckstrom, A., Steiner, D.F. (1996). Effects of beta cell granule components on human islet amyloid polypeptide fibril formation. FEBS Lett, 379, 203-206.
50. Janciauskiene, S., Eriksson, S., Carlemalm, E., Ahren, B. (1997). b-cell granule peptides affect human islet amyloid polypeptide (IAPP) fibril formation in vitro. Biochem Biophys Res Commun, 236, 580-585.
51. Jaikaran, E., Nilsson, M., Clark, A. (2004). Pancreatic b-cell granule peptides form heteromolecular complexes which inhibit islet amyloid polypeptide fibril formation. Biochem J, 377, 709-716.
52. Larson, J., Miranker, A.D. (2004). The mechanism of insulin action on islet amyloid polypeptide fiber formation. J Mol Biol, 335, 221-231.
53. Gilead, S., Wolfenson, H., Gazit, E. (2006). Molecular mapping of the recognition interface between the islet amyloid polypeptide and insulin. Angew Chem Int Ed Engl, 45, 6476-6480.
54. Betsholtz, C., Christmansson, L., Engstrom, U., Rorsman, F., Svensson, V., Johnson, K.H., Westermark, P. (1989). Sequence divergence in a specific region of islet amyloid polypeptide (IAPP) explains differences in islet amyloid formation between species. FEBS Lett, 251, 261-264.
55. Betsholtz, C., Christmanson, L., Engström, U., Rorsman, F., Jordan, K., O'Brian, T.D., Murtaugh, M., Johnson, K.H., Westermark, P. (1990). Structure of cat islet amyloid polypeptide and identification of amino acid residues of potential significance for islet amyloid formation. Diabetes, 39, 118-122.
56. Westermark, P., Engström, U., Johnson, K.H., Westermark, G.T., Betsholtz, C. (1990). Islet amyloid polypeptide: pinpointing amino acid residues linked to amyloid fibril formation. Proc Natl Acad Sci U S A, 87, 5036-5040.
57. Grenner, G.G., Eanes, E.D., Wiley, C.A. (1988). Amyloid fibrils formed from a segment of the pancreatic-islet amyloid protein. Biochem Biophys Res Commun, 155, 608-614.
58. Minor, D.L., Jr., Kim, P.S. (1994). Measurement of the beta-sheet-forming propensities of amino acids. Nature, 367, 660-663.
59. Nilsson, M.R., Raleigh, D.P. (1999). Analysis of amylin cleavage products provides new insights into the amyloidogenic region of human amylin. J Mol Biol, 294, 1375-1385.
60. Jaikaran, E., Higham, C.E., Serpell, L.C., Zurdo, J., Gross, M., Clark, A., Fraser, P.E. (2001). Identification of a novel human islet amyloid polypeptide b-sheet domain and factors influencing fibrillogenesis. J Mol Biol, 308, 515-525.
61. Tracz, S.M., Abedini, A., Driscoll, M., Raleigh, D.P. (2004). The role of aromatic interactions in amyloid formation by polypeptides: analysis of peptides derived from human amylin. Biochemistry, 43, 15901-15908.
62. Abedini, A., Raleigh, D.P. (2006). Destabilization of human IAPP amyloid fibrils by proline mutations outside of the putative amyloidogenic domain: is there a critical amyloidogenic domain in human IAPP? J Mol Biol, 355, 274-281.
63. Green, J., Goldsbury, C., Mini, T., Sunderji, S., Frey, P., Kistler, J., et al. (2003). Full-length rat amylin forms fibrils following substitution of single residues from human amylin. J Mol Biol, 326, 1147-1156.
64. Gazit, E. (2002). A possible role for pi-stacking in the self-assembly of amyloid fibrils. FASEB J, 16, 77-83.
65. Azriel, R., Gazit, E. (2001). Analysis of the minimal amyloid-forming fragment of the islet amyloid polypeptide. J Biol Chem, 276, 34156-34161.
66. Reches, M., Porat, Y., Gazit, E. (2002). Amyloid fibril formation by pentapeptide and tetrapeptide fragments of human calcitonin. J Biol Chem, 277, 35475-35480.
67. Bemporad, F., Taddei, N. Steffani, M., Chiti, F. (2006). Assessing the role of aromatic residues in the amyloid aggregation of human muscle acylphosphatase. Protein Sci,15, 862-870.
68. Marek, P., Abedini, A., Song, B., Kanungo, M., Johnson, M.E., Gupta, R., Zaman, W., Wong, S.S., Raleigh, D.P. (2007). Aromatic interactions are not required for amyloid fibril formation by islet amyloid polypeptide but do influence the rate of fibril formation and fibril morphology. Biochemistry, 46, 3255-3261.
69. Padrick, S.B., Miranker, A.D. (2001). Islet amyloid polypeptide: identification of long-range contacts and local order on the fibrillogenesis pathway. J Mol Biol, 308, 783-794.
70. Goldsbury, C.S., Cooper, G.J.S., Goldie, K.N., Muller, S.A., Saafi, E.L., Gruijters, W.T.M., Misur, M.P. (1997). Polymorphic fibrillar assembly of human amylin. J Struct Biol, 119, 17-27.
71. Goldsbury, C., Kistler, J., Aebi,U., Arvinte, T., Cooper, G.J.S. (1999). Watching amyloid fibrils grow by timelapse atomic force microscopy. J Mol Biol, 285, 33-39.
72. Goldsbury, C., Goldie, K., Pellaud, J., Seelig, J., Frey, P., Muller, S.A., Kistler, J., Cooper, G.J.S., Aebi, U. (2000). Amyloid fibril formation from full-length and fragments of amylin. J Struct Biol, 130, 352-362.
73. Makin, S.O., Serpell, L.C. (2004). Structural characterization of islet amyloid polypeptide fibrils. J Mol Biol, 335, 1279-1288.
74. Luca, S., Yau, W.-M., Leapman, R., Tycko, R. (2007). Peptide conformation and supramolecular organization in amylin fibrils: constraints from solid-state NMR. Biochemistry, 46, 13505-13522.
75. Jayasinghe, S.A., Langen, R. (2004). Identifying structural features of fibrillar islet amyloid polypeptide using site-directed spin labeling. J Biol Chem, 279, 48420-48425.
76. Kajava, A.V., Aebi, U., Steven, A.C. (2005). The parallel superpleated beta structure as a model for amyloid fibrils of human amylin. J Mol Biol, 348, 247-252.
77. Yoder, M.D., Keen, N.T., Jurnak, F. (1993). New domain motif: the structure of pectate lyase C, a secreted plant virulence factor. Science, 260, 1503-1507.
78. Gordon, D.J., Balbach, J.J., Tycko, R., Meredith, S.C. (2004). Increasing the amphiphilicity of an amyloidogenic peptide changes the beta-sheet structure in the fibrils from antiparallel to parallel. Biophys J, 86, 428-434.
79. Oosawa, F., Asakura, S. (1975). Thermodynamics of the Polymerization of Protein, Academic Press, New York.
80. Ferrone, F. (2006). Nucleation: the connections between equilibrium and kinetic behavior. Methods Enzymol, 412, 285-299.
81. Mozzarelli, A., Hofrichter, J., Eaton, W.A. (1987). Delay time of hemoglobin-S polymerization prevents most cells from sickling in vivo. Science, 237, 500-506.
82. Padrick, S.B., Miranker, A.D. (2002). Islet amyloid: phase partitioning and secondary nucleation are central to the mechanism of fibrillogenesis. Biochemistry, 41, 4694-4703.
83. Hong, D.P., Hoshino M., Kuboi R., Goto Y. (1999). Clustering of fluorinesubstituted alcohols as a factor responsible for their marked effects on proteins and peptides. J Am Chem Soc, 121, 8427-8433.
84. Yoshida, K., Yamaguchi, T., Adachi, T., Otomo, T., Matsuo, D., Takamuku, T. Nishi, N. (2003). Structure and dynamics of hexafluoroisopropanol-water mixtures by x-ray diffraction, small-angle neutron scattering, NMR spectroscopy, and mass spectrometry. J Chem Phys, 119, 6132-6142.
85. Powers, E.T., Powers, D.L. (2006). The kinetics of nucleated polymerizations at high concentrations: amyloid fibril formation near and above the "supercritical concentration." Biophys J, 91, 122-132.
86. Westermark, P., Eizirik, D.L., Pipeleers, D.G., Hellersrom, C., Anderson, A. (1994). Rapid deposition of amyloid in human islets transplanted into nude mice. Diabetologia, 38, 543-549.
87. Westermark, P., Andersson, A., Westermark, G. (2005). Is aggregated IAPP a cause of beta-cell failure in transplanted human pancreatic islets? Cur Diabetes Rep, 5, 185-188.
88. Westermark, G.T., Westermark, P., Nordin A., Tornelius E., Andersson, A. (2003). Formation of amyloid in human pancreatic islets transplanted to the liver and spleen of nude mice. Upsala J Med Sci, 108, 193-203.
89. Ma, Z., Westermark, G.T., Sakagashira, S., Sanke, T., Gustavsson, A., Sakamoto, H., Engstrom, U., Nanjo, K., Westermark, P. (2001). Enhanced in vitro production of amyloid-like fibrils from mutant (S20G) islet amyloid polypeptide. Amyloid, 8, 242-249.
90. Matveyenko, A.V., Butler, P.C. (2007). Islet amyloid polypeptide (IAPP) transgenic rodents as models for type 2 diabetes. ILAR J, 47, 225-233.
91. Young, I.D., Ailles, L., Narindrasorasak, S., Tan, R., Kisilevsky, R. (1992). Localization of the basement membrane heparan sulfate proteoglycan in islet amyloid deposits in type II diabetes mellitus. Arch Pathol Lab Med, 116, 951-954.
92. Conde-Knape, K. (2001). Heparan sulfate proteoglycans in experimental models of diabetes: a role for perlecan in diabetes complications. Diabetes Metab Res Rev, 17, 412-421.
93. Potter-Perigo, S., Hull, R.L., Tsoi, C., Braun, K.R., Andrikopoulos, S., Teague, J., Verchere, C.B., Kahn, S.E., Wright, T.N. (2003). Proteoglycans synthesized and secreted by pancreatic islet b-cells bind amylin. Arch Biochem Biophys, 413, 182-190.
94. Vidal, J., Verchere, C.B., Andrikopoulos, S., Wang, F., Hull, R.L., Cnop, M., Olin, K.L., LeBoeuf, R.C., O'Brian, K.D., Chait, A., Khan, S.E. (2003). The effect of apolipoprotein E deficiency on islet amyloid deposition in human islet amyloid polypeptide transgenic mice. Diabetologica, 46, 71-79.
95. Pepys, M.B., Booth, D.R., Hutchinson, W.L., Gallimore, J.R., Collins, P.M., Hohenester, E. (1997). Amyloid P component: a critical review. Amyloid: Int J Exp Clin Invest, 4, 274-295.
96. Schmechel, D.E., Saunders, A.M., Strittmatter, W.J., Crain, B.J., Hulette, C.M., Joo, S.H., Pericak-Vance, M.A., Goldgaber, D., Roses, A.D. (1993). Increased amyloid b-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci U S A, 90, 9649-9653.
97. Bales, K.R., Verina, T., Cummins, D.J., Du, Y., Dodel, R.C., Saura, J., Fishman, C.E., DeLong, C.A., Piccardo, P., Petegnief, V., et al. (1997). Lack of apolipoprotein E dramatically reduces amyloid b-peptide deposition. Nat Genet, 17, 263-264.
98. Eto, M., Watanabe, K., Makino, I., Ishii, K. (1991). Apolipoprotein E allele frequencies in non-insulin-dependent diabetes mellitus with hypertriglyceridemia (type IIb, III, IV, and V hyperlipoproteinemia). Metabolism, 40, 776-780.
99. Inamdar, P.A., Kelkar, S.M., Devasagayam, T.P., Bapat, M.M. (2000). Apolipoprotein E polymorphism in non-insulin-dependent diabetes of Mumbai, India and its effect on plasma lipids and lipoproteins. Diabetes Res Clin Pract, 47, 217-223.
100. Paulsson, J.F., Westermark, G.T. (2005). Aberrant processing of human proislet amyloid polypeptide results in increased amyloid formation. Diabetes, 54, 2117-2125.
101. Paulsson, J.F., Andersson, A., Westermark, P., Westermark, G.T. (2006). Intracellular amyloid-like deposits contain unprocessed pro-islet amyloid polypeptide (proIAPP) in beta cells of transgenic mice overexpressing the gene for human and transplanted human islets. Diabetologia, 49, 1237-1246.
102. Marzban, L., Rhodes, C., Steiner, D., Haataja, L., Halban, P., Verchere, C.B. (2006). Impaired NH2-terminal processing of human proislet amyloid polypeptide by the prohormone convertase PC2 leads to amyloid formation and cell death. Diabetes, 55, 2192-2201.
103. Kahn, S.E. (1997). Release of incompletely processed proinsulin is the cause of the disproportionate proinsulinemia of NIDDM. Diabetes, 46, 1725-1732.
104. Zhu, X., Orci, L., Carroll, R., Norrbom, C., Ravazzola, M., Steiner, D.F. (2002). Severe block in processing of proinsulin to insulin accompanied by elevation of des-64, 65 proinsulin intermediates in islets of mice lacking prohormone convertase PC1/3. Proc Natl Acad Sci U S A, 99, 10299-10304.
105. Westermark, G.T., Steiner, D.F., Gebre-Medhin, S., Engström, U., Westermark, P. (2000). Proislet amyloid polypeptide immunoreactivity in the islets of Langerhans. Upsala J Med Sci, 105, 97-106.
106. Westermark, P., Engström, U., Westermark, G.T., Johnson, K.H., Permerth, J., Betsholtz, C. (1989). Islet amyloid polypeptide (IAPP) and pro-IAPP immunoreactivity in human islets of Langerhans. Diabetes Res Clin Pract, 7, 219-226.
107. Park, K., Verchere, C.B. (2001). Identification of a heparin binding domain in the N-terminal cleavage site of pro-islet amyloid polypeptide. J Biol Chem, 276, 16611-16616.
108. Ancsin, J.B. (2003). Amyloidogenesis: historical and modern observations point to heparan sulfate proteoglycans as a major culprit. Amyloid, 10, 67-79.
109. Meng, F., Abedini, A., Raleigh, D. P. (2007). Amyloid formation by pro-islet amyloid polypeptide processing intermediates: examination of the role of protein heparan sulfate interactions and implications for islet amyloid formation in type 2 diabetes. Biochemistry, 46, 12091-12099.
110. Kirkitadze, M.D., Condron, M.M., Teplow, D.B. (2001). Identification and characterization of key kinetic intermediates in amyloid b-protein fibrillogenesis. J Mol Biol, 312, 1103-1109.
111. Hull, R., Zraika, S., Udayasankar, J., Kisilevsky, R., Szarek, W., Wight, T., Kahn, S.E. (2007). Inhibition of glucosaminoglycan synthesis and protein glycosylation with WAS-406 and azaserine result in reduced islet amyloid formation in vitro. Amer J Phys Cell Physiol, 293, C1586-C1593.
112. Mirzabekov, T.A., Lin, M.C., Kagan, B.L. (1996). Pore formation by the cytotoxic islet amyloid peptide amylin. J Biol Chem, 271, 1988-1992.
113. Harroun, T.A., Bradshaw, J.P., Ashley, R.H. (2001). Inhibitors can arrest the membrane activity of human islet amyloid polypeptide independently of amyloid formation. FEBS Lett, 507, 200-204.
114. Anguiano, M., Nowak, R.J., Lansbury, P.T. (2002). Protofibrillar islet amyloid polypeptide permeabilizes synthetic vesicles by a pore-like mechanism that may be relevant to type II diabetes. Biochemistry, 41, 11338-11343.
115. Jayasinghe, S.A., Langen, R. (2005). Lipid membranes modulate the structure of islet amyloid polypeptide. Biochemistry, 44, 12113-12119.
116. Balali-Mood, K., Ashley, R.H., Hauss, T., Bradshaw, J.P. (2005). Neutron diffraction reveals sequence-specific membrane insertion of pre-fibrillar islet amyloid polypeptide and inhibition by rifampicin. FEBS Lett, 579, 1143-1148.
117. Engel, M.F.M., Yigittop, H., Elgersma, R.C., Rijkers, D.T.S., Liskamp, R.M.J., De Kruijff, B., Hoeppener, J.W.M., Antoinette Killian, J. (2006). Islet amyloid polypeptide inserts into phospholipid monolayers as monomer. J Mol Biol, 356, 783-789.
118. Knight, J.D., Hebda, J.A., Miranker, A.D. (2006). Conserved and cooperative assembly of membrane bound a-helical states of islet amyloid polypeptide. Biochemistry, 45, 9496-9508.
119. Lopes, D.H.J., Meister, A., Gohlke, A., Hauser, A., Blume, A., Winter, R. (2007). Mechanism of islet amyloid polypeptide fibrillation at lipid interfaces studied by infrared reflection absorption spectroscopy. Biophys J, 93, 3132-3141.
120. Jayasinghe, S.A., Langen, R. (2007). Membrane interactions of islet amyloid polypeptide. Biochim Biophys Acta, 1768, 2002-2009.
121. Sparr, E., Engel, M.F.M., Sakharov, D.V., Sprong, M., Jacobs, J., de Kruijff, B., Hoppener, J.W.M., Antoinette Killian, J. (2004). Islet amyloid polypeptideinduced membrane leakage involves uptake of lipids by forming amyloid fibers. FEBS Lett, 577, 117-120.
122. Porat, Y., Kolusheva, S., Jelinek, R., Gazit, E. (2003). The human islet amyloid polypeptide forms transient membrane-active prefibrillar assemblies. Biochemistry, 42, 10971-10977.
123. Green, J.D., Kreplan, L., Goldsbury, C., Blatter, X.L., Stolz, M., Cooper, G.J.S., Seelig, A., Kistler, J., Aebi, U. (2004). Atomic force microscopy reveals defects within mica supported lipid bilayers induced by the amyloidogenic human amylin peptide. J Mol Biol, 342, 877-887.
124. Kayed, R., Sokolov, Y., Edmonds, B., McIntire, T.M., Milton, S.C., Hall, J.E., Glabe, C.G. (2004). Permeabilization of lipid bilayers is a common conformationdependent activity of soluble amyloid oligomers in protein misfolding disease. J Biol Chem, 279, 46363-46366.
125. Rustenbeck, I., Matthies, A., Lenzen, S. (1994). Lipid composition of glucosestimulated pancreatic islets and insulin-secreting tumor cells. Lipids, 29, 685-692.
126. Hubbard, J., Martin, S., Chaplin, L.C., Bose, C., Kelly, S.M., Prince, N.C. (1991). Solution structures of calcitonin-gene-related-peptide analogs of calcitonin-generelated peptide and amylin. Biochem J, 275, 785-788.
127. Williamson, J.A., Miranker, A.D. (2007). Direct detection of transient a-helical states in islet amyloid polypeptide. Protein Sci, 16, 1-8.
128. Cort, J., Liu, Z., Lee, G., Harris, S.M., Prickett, K.S., Gaeta, S.L., Andersen, N.H. (1994). b-Structure in human amylin and two designer b-peptides: CD and NMR spectroscopic comparisons suggests soluble b-oligomers and the absence of significant population of b-strand dimers. Biochem Biophys Res Commun, 204, 1088-1095.
129. Breeze, A.L., Harvey, T.S., Bazzo, R., Campbell, I.D. (1991). Solution structure of human calcitonin gene-related peptide by H-1-NMR and distance geometry with restrained molecular-dynamics. Biochemistry, 30, 575-582.
130. Abedini, A., Raleigh, D.P. (2009). A role for helical intermediates in amyloid formation by natively unfolded polypeptides? Phys Biol, 6, 15005.
131. Eliezer, D. (2006). Amyloid ion channels: a porous argument or a thin excuse? J Gen Physiol, 128, 631-636.
132. Lansbury, P.T., Lashuel, H.A. (2006). A century-old debate on protein aggregation and neurodegeneration enters the clinic. Nature, 443, 774-779.
133. Rochet, J. (2007). Novel therapeutic strategies for the treatment of proteinmisfolding diseases. Expert Rev Mol Med, 9, 1-31.
134. Kapurniotu, A., Schmauder, A., Tenidis, K. (2002). Structure-based design and study of non-amyloidogenic, double N-methylated IAPP amyloid core sequences as inhibitors of IAPP amyloid formation and cytotoxicity. J Mol Biol, 315, 339-350.
135. Rijkers, D.T.S., Hoppener, J.W.M., Posthuma, G., Lips, C.J.M., Kiskamp, R.M.J. (2002). Inhibition of amyloid fibril formation of human amylin by N-alkylated amino acid and alpha-hydroxy acid residue containing peptides. Chemistry, 8, 4285-4291.
136. Porat, Y., Mazor, Y., Efrat, S., Gazit, E. (2004). Inhibition of islet amyloid polypeptide fibril formation: a possible role for hetero-aromatic interactions. Biochemistry, 43, 14454-14462.
137. Scrocchi, L.A., Chen, Y., Waschuk, S., Wang, F., Cheung, S., Darabie, A.A., McLaurin, J., Fraser, P.E. (2002). Design of peptide-based inhibitors of human islet amyloid polypeptide fibrillogenesis. J Mol Biol, 318, 697-706.
138. Cohen, T., Frydman-Marom, A., Rechter, M., Gazit, E. (2006). Inhibition of amyloid fibril formation and cytotoxicity by hydroxyindole derivatives. Biochemistry, 45, 4727-4735.
139. Scrocchi, L.A., Chen, Y., Wang, F., Han, K., Ha, K., Fraser, P.E. (2003). Inhibitors of islet amyloid polypeptide fibrillogenesis, and the treatment of type-2 diabetes. Lett Pept Sci, 10, 545-551.
140. Aiteken, J.F., Lommes, K.M., Konarkowska, B., Cooper, G.J.S. (2003). Suppression by polycyclic compounds of the conversion of human amylin into insoluble amyloid. Biochem J, 374, 779-784.
141. Gazit, E. (2005). Mechanisms of amyloid fibril self-assembly and inhibition. FASEB J, 272, 5971-5978.
142. Dember, L.M., Hawkins, P.N., Hazenberg, B.P., Gorevic, P.D., Merlini, G., Butrimiene, I., Livneh, A., Lesnyak, O., Puećhal, X., Lachmann, H.J., et al., Eprodisate for AA Amyloidosis Trial Group. (2007). Eprodisate for the treatment of renal disease in AA amyloidosis. N Engl J Med, 356, 2349-2359.
143. Abedini, A., Meng, F., Raleigh, D.P. (2007). A single-point mutation converts the highly amyloidogenic human islet amyloid polypeptide into a potent fibrillization inhibitor. J Am Chem Soc, 129, 11300-11301.
144. Yan, L.M., Tatarek-Nossol, M., Velkova, A., Kazantzis, A., Kapurniotu, A. (2006). Design of a mimic of nonamyloidogenic and bioactive human islet amyloid polypeptide (IAPP) as a nanomolar affinity inhibitor of IAPP cytotoxic fibrillogenesis. Proc Natl Acad Sci U S A, 103, 2046-2051.
145. Yan, L.M, Velkova, A., Tatarek-Nossol, M., Andreetto, E., Kapurniotu, A. (2007). IAPP mimic blocks Ab cytotoxic self-assembly: cross-suppression of amyloid toxicity of Ab and IAPP suggests a molecular link between Alzheimer's disease and type II diabetes. Angew Chem Int Ed Engl, 46, 1246-1252.
146. Ratner R.E., Dickey R., Fineman M., Maggs D.G., Shen L., Strobel S.A., Weyer C., Kolterman O.G. (2004). Amylin replacement with pramlintide as an adjunct to insulin therpy improves long-term glycaemic and weight control in type-1 diabetes mellitus: a 1-year, randomized controlled trial. Diabetes Med, 21, 1204-1212.
147. Allard, F.D., Wallace, A.E., Greenbaum, G.J. (2005). Emerging therapies: going beyond insulin in treating individuals with type-I diabetes mellitus. Curr Opin Endocrinol Diabetes, 12, 303-308.